ACE and chronic kidney disease: A meta-analysis of randomized clinical trials held by Zhang et al. found that ACE inhibitors are superior to ARBs in delaying the progression of CKD to ESRD, reducing cardiovascular events, cardiovascular death, and all-cause death in non-dialysis patients with stage 3-5 CKD, while in diabetic advanced CKD patients, ARBs were superior to ACEIs in reducing the progression of CKD and cardiovascular outcomes but inferior to ACEIs in lowering all-cause mortality [61].